(Q42599423)

English

Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.

scientific article published on January 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

1

object named as

James C Ermer

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

3

object named as

Mary B Haffey

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

author name string

Kerry Dennis

2

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Walter J Doll

4

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Erik P Sandefer

5

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Mary Buckwalter

6

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Richard C Page

7

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Brian Diehl

8

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Patrick T Martin

9

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

publication date

1 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Clinical Drug Investigation

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

357-370

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, cro

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Abuse of prescription drugs and the risk of addiction

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD.

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Nasal route and drug delivery systems

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.2165%2F11588190-000000000-00000

21 January 2018

Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21539403

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacotherapy of attention deficit hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/21539403

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21539403

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21539403

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The worldwide prevalence of ADHD: a systematic review and metaregression analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21539403

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11588190-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42599423&oldid=2143347894"